EMA 2024: European Parliament approves accounts and what it means for the pharmaceutical sector

Key data

The European pharmaceutical industry operates under the supervision of the European Medicines Agency (EMA), the body that evaluates and authorizes medicines throughout the European Union. On 29 April 2026, the European Parliament formally approved the EMA's budget management for the 2024 financial year, through Decision (EU) 2026/1631, published in the Official Journal on 10 September 2026.

This type of decision, known as a "budget discharge", closes the agency's annual accounting cycle. The result is positive: auditors and parliamentarians have considered the budget execution satisfactory. No corrective measures have been imposed and no irregularities have been detected that affect the agency's operations.

What does this regulation establish?

The discharge procedure is a mechanism of democratic and financial control provided for in the EU Financial Regulation. Each year, the European Parliament reviews the budget execution of European agencies and issues a formal decision of approval or rejection.

In the case of the EMA for 2024, the decision establishes the following:

• The European Parliament approves the budget management of the EMA for the 2024 financial year.
• Auditors and Parliament have considered the agency's budget execution satisfactory.
• The positive discharge formally closes the budget cycle for the 2024 financial year.
• No significant corrective measures are imposed and no changes in agency management are required.
• The decision confirms the institutional and operational stability of the EMA as the European pharmaceutical regulator.

In practical terms, this decision does not modify any previous rule or introduce new obligations for companies. It is a validation of the agency's functioning, not a regulatory reform.

Economic and operational impact

For pharmaceutical and healthcare sector companies, the EMA's positive discharge has indirect but relevant implications:

• No changes in fees or procedures: Approval without objection means that no urgent reviews of the fees charged by the EMA for medicine evaluation, clinical trials or marketing authorizations are anticipated.
• Regulatory continuity guaranteed: A negative discharge could have triggered additional audits, internal restructuring or temporary suspension of procedures. None of this will occur.
• Signal of stability for investors and operators: Companies with open files at the EMA—authorizations, variations, renewals—can plan their regulatory calendars without added institutional uncertainty.
• No direct impact on operating costs: This decision does not generate new economic burdens for companies in the sector.

The positive discharge is, ultimately, a confirmation that the EMA is functioning normally and that the European regulatory framework for medicines remains stable for the current financial year.

Who does it affect?

• Pharmaceutical laboratories with marketing authorizations or files in process at the EMA.
• Biotechnology companies developing medicines for human or veterinary use in the EU.
• National regulatory bodies (such as AEMPS in Spain) that collaborate with the EMA in centralized procedures.
• Pharmaceutical distributors and wholesalers whose operations depend on authorizations issued by the EMA.
• Investors and specialized health sector funds that monitor the institutional stability of the European regulator.
• Regulatory consultancies and regulatory affairs advisors that manage files at the EMA on behalf of their clients.

Practical example

A Spanish pharmaceutical laboratory has a centralized authorization application pending at the EMA for a new oncology medicine. The process has been underway for 18 months and is in the evaluation phase by the Committee for Medicinal Products for Human Use (CHMP).

With the positive discharge of the 2024 accounts, this laboratory can confirm that:

• The EMA operates with institutional and financial normality, with no risk of suspension due to audits or restructuring.
• The regulatory timelines provided for its file will not be altered by internal management issues at the agency.
• No changes in evaluation fees are anticipated that could affect the regulatory budget of the project.

In practical terms, the company can maintain its regulatory roadmap without needing to review contingencies related to the stability of the European regulator.

What should companies do now?

1. Confirm the stability of regulatory calendars: Companies with open files at the EMA can maintain their timeline forecasts without modifications resulting from this decision.
2. Review the status of your current authorizations: Take advantage of the confirmation of the EMA's operational normality to update the inventory of marketing authorizations and their renewal status.
3. Monitor the EMA's budget for 2025: Although the 2024 discharge is positive, the next budget cycle may introduce changes in fees or resources. Following publications on the EMA official website is recommended.
4. Inform regulatory affairs teams: Communicate to those responsible for regulatory affairs the confirmation of institutional stability so they can incorporate it into their regulatory risk reports.
5. No urgent actions required: This decision does not impose adaptation deadlines or new obligations. There is no risk of non-compliance directly resulting from this regulation.

Official source

Consult complete regulation in official source

Disclaimer: This article is for informational purposes only and does not constitute legal advice. For specific decisions, consult a qualified professional. Source: https://eur-lex.europa.eu/./legal-content/AUTO/?uri=OJ:L_202601631